Cresflut price and purchase channel recommendations

Crinecerfont, trade name Crenessity, is an innovative corticotropin-releasing factor 1 type receptor antagonist, as a glucocorticoid As an adjuvant therapy for hormone replacement therapy, Cresflutide is mainly used to control androgen levels in adults and children aged 4 and above with typical congenital adrenal hyperplasia (CAH), providing patients with new treatment options.

Crisflutide is suitable for patients 4 years old and aboveCAH to control androgen levels. For children under 4 years old, its safety and effectiveness have not been confirmed, so its use is not recommended.

It is worth mentioning that Crenessity (trade nameCrenessity) has been approved for marketing by the US Food and Drug Administration FDA on December 13, 2024. However, due to the short time on the market, the specific price has not yet been determined. Patients and family members can pay attention to the official website of the FDA or relevant medical news for the latest information. For patients who are in urgent need of medication, it is recommended to consult a regular overseas medical consulting agency to understand the purchasing methods and procedures.

The most common adverse reactions when using crisflutide in adult patients include fatigue, headache, dizziness, joint pain, back pain, decreased appetite, and myalgia. Pediatric patients may experience adverse reactions such as headache, abdominal pain, fatigue, nasal congestion, and epistaxis.

During medication, patients need to pay special attention to allergic reactions, such as throat tightness, angioedema, and generalized rash. If such a reaction occurs, the drug should be discontinued immediately and appropriate treatment should be received. At the same time, glucocorticoids should be continued during crisflutide treatment to avoid the risk of acute adrenal insufficiency or adrenal crisis. Any adjustment in glucocorticoid dosage should be made under the supervision of a medical professional.

Crisflutide providesCAH patients with a new treatment option. While paying attention to drug prices, patients and family members should fully understand its indications, side effects and medication precautions to ensure safe and effective medication. We look forward to the drug being approved in China in the future and benefiting more patients.

Reference link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218808s000,218820s000lbl.pdf